CORRECTION Open Access

Correction: MicroRNA-30a-5p^{me}: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples

Gonçalo Outeiro-Pinho^{1,2†}, Daniela Barros-Silva^{1†}, Elena Aznar^{1,3}, Ana-Isabel Sousa¹, Márcia Vieira-Coimbra¹, Jorge Oliveira⁴, Céline S. Gonçalves^{5,6}, Bruno M. Costa^{5,6}, Kerstin Junker⁷, Rui Henrique^{1,8,9} and Carmen Jerónimo^{1,9*}

Correction: J Exp Clin Cancer Res 39, 98 (2020) https://doi.org/10.1186/s13046-020-01600-3

Following publication of the original article [1], an error was identified in Supplementary Figure 1 where incorrectly labelled graphs were found; specifically:

 Supplementary Figure 1: the y axis is currently labelled as miR-30c-5p expression (normalized to RNU48) whereas it should be labelled as miR-30a-5p expression (normalized to RNU48); correct supplementary file is now used

The correction does not have any effect on the results or conclusions of the paper. The original article has been corrected.

The original article can be found online at https://doi.org/10.1186/s13046-020-01600-3.

 † Gonçalo Outeiro-Pinho and Daniela Barros-Silva are joint first authors.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13046-022-02450-x.

Additional file 1: Supplementary Figure S1. Expression of miR-30a-5p according to clinicopathological variables in Cohort #1. Scatter plots of miR-30a-5p expression levels according to metastasis presentation, recurrence and Führman grade (Mann–Whitney U test).

Author details

Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. ²Master in Molecular Medicine and Oncology, Faculty of Medicine-University of Porto (FMUP), Porto, Portugal. ³Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat de València, CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Camino de Vera s/n, 46022 Valencia, Spain. ⁴Department of Urology, Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António, Bernardino de Almeida, 4200-072 Porto, Portugal. ⁵Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, Braga, Portugal. ⁶ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, University of Minho, Campus de Gualtar, Braga, Portugal. ⁷Department of Urology and Pediatric Urology, Saarland University, Homburg, Saar, Germany. 8Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal. ⁹Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira n. 228, 4050-313 Porto, Portugal.

Published online: 15 August 2022

Reference

 Outeiro-Pinho G, Barros-Silva D, Aznar E, et al. MicroRNA-30a-5p^{me}: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples. J Exp Clin Cancer Res. 2020;39:98. https://doi.org/10.1186/s13046-020-01600-3.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeccommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: carmenjeronimo@ipoporto.min-saude.pt

¹ Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal

⁹ Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira n. 228, 4050-313 Porto, Portugal Full list of author information is available at the end of the article